| Dosage Form: | Powder Injection |
|---|---|
| Transport Package: | Carton |
| Specification: | 2.5g |
| Trademark: | Sinolead |
| Origin: | China |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Generic Name | Ceftazidime and Avibactam Sodium for Injection |
| Strength | 2.5g |
| Packing | 10 vials/box |
| Origin | China |
1. Complex Intraperitoneal Infection (cIAI)
This product is indicated in combination with metronidazole for the treatment of gram-negative bacteria sensitive to this product in patients 18 years of age and older
Complex intraperitoneal infections caused by: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae,
Klebsiella acidogenes, Citrobacter Frei complex and Pseudomonas aeruginosa.
2. Hospital-acquired pneumonia and Ventilator-associated pneumonia (HAP/VAP)
This product is intended for use in hospitals treating patients 18 years of age and older caused by the following gram-negative bacteria that are sensitive to this product
Acquired and ventilator-associated pneumonia: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, clay sand
Fulminella, Proteus mirabilis, pseudomonas aeruginosa and Haemophilus influenzae.
3. In adult patients with limited treatment options, treatment is caused by the following gram-negative bacteria that are sensitive to this product
Infections: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Proteus mirabilis and Pseudomonas aeruginosa.
This indication is based on the experience of ceftazidime alone and the pharmacokinetics of ceftazidime/avibactam
Analysis of the relationship between science and pharmacodynamics. Only physicians with extensive experience in the treatment of infectious diseases should use this product for this adaptation
The treatment of disease. In order to reduce the appearance of resistant bacteria and maintain the effectiveness of this product and other antimicrobial agents, this product is intended for treatment only
To treat infections that are confirmed or highly suspected to be caused by sensitive bacteria. It should be selected or adjusted according to the new culture and drug sensitivity results
Medicine. In the absence of such data, local epidemiology and drug resistance analysis may be useful for empirical selection
Heal.
Complex intraperitoneal infection 2,3[combined with metronidazole]
2.5g(2g/0.5g) every 8 hours for 25 to 14 days hospital-acquired pneumonia and ventilator-associated pneumonia
2.5g(2g/0.5g) once every 8 hours for infection caused by aerobic gram-negative bacteria in adult patients with limited treatment options for 27 to 14 days
Old people
Elderly people do not need to adjust the dose (see Pharmacokinetics).
Patients with renal impairment Patients with mild renal impairment do not need to adjust the dose (50mL/min kinetics).
The recommended dose adjustments for patients with eCrCL≤50mL/min are shown in Table 2 for renal function changes
In patients with diabetes, CrCL should be monitored at least daily and the dose of this product adjusted accordingly (see "Precautions" and "Drugs")
The dynamics of generation.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}